Do you lose more weight on a higher dose of Wegovy?

Does the weight loss really increase as the dose goes up?

The short answer is yes, on average, and the trial data back it up clearly. The STEP 1 study, published in the New England Journal of Medicine, followed adults with obesity over 68 weeks. Participants who completed the full titration to 2.4mg lost roughly 15% of their starting weight, a result meaningfully larger than what earlier-phase participants achieved before reaching that dose.

The mechanism behind this is straightforward. Semaglutide, the active ingredient in Wegovy, activates GLP-1 receptors that slow gastric emptying and reduce appetite. Higher concentrations in the bloodstream produce a stronger appetite-suppressing effect. That is why the titration schedule exists at all: the 0.25mg starting dose is not designed to drive weight loss, its job is to let your digestive system adapt before the therapeutic doses begin.

It is worth knowing that the newer 7.2mg Wegovy pen, approved by the MHRA on 14 April 2026, pushed average results further still, with trials reporting around 20.7% average weight loss over 72 weeks. That is notably closer to tirzepatide territory. You can read more about what the higher Wegovy dose means in practice and whether it might be relevant to your own treatment.

None of this means higher is always better for you specifically. Individual response varies, and a number that looks impressive in a trial cohort is an average, not a prediction.

What happens at lower doses, is any weight loss possible before 2.4mg?

This is something our prescribers are asked most weeks, and it is a fair question. Many people do lose measurable weight before they reach the maintenance dose. The titration steps (0.25mg, 0.5mg, 1mg, 1.7mg) are not just waiting rooms. At each level, appetite suppression begins to take effect, and eating patterns often shift well before 2.4mg is reached.

Clinical data on the intermediate doses are less detailed than at the endpoint, but the trajectory is consistent: weight loss at the 1.7mg stage is real for a significant number of people, and some individuals are managed at that dose long-term if side-effect tolerance makes moving higher unsuitable. Similarly, lower doses do produce results for some people, even if the averages at trial endpoint are smaller.

The honest framing is this: you are more likely to see greater weight loss at higher doses, but the journey to those doses takes time, and progress during the climb counts. Trying to rush titration to get to 2.4mg faster typically increases side effects without a proportional gain in results, the digestive system needs the adjustment period.

Are there situations where a higher dose is not the right move?

Yes, and this is where the individualised nature of prescribing matters most. If nausea, vomiting or other gastrointestinal effects are significant at a given dose, your prescriber may hold you at that level for an additional four weeks rather than moving up on schedule. That is a clinically sound decision, not a setback.

There are also people for whom the response plateaus despite reaching the highest tolerated dose. NICE's guidance on semaglutide (TA875) is explicit: if a patient has not achieved at least 5% weight loss after six months on the maintenance dose, continuing should be reconsidered. This reflects the reality that no medicine works identically for everyone, and responsible clinical oversight includes that honest review.

It also underlines why having a prescriber who actually reviews your progress (not just renews your prescription automatically) matters. At nume, every repeat order goes through our clinical team before dispatch; dose increases specifically require evidence that the progression is appropriate. If you are wondering whether moving to a higher dose is right for you, that conversation belongs with your prescriber rather than on a forum or a product page.

If cost is a factor in how you think about dose, the Wegovy pricing guide sets out what affects the figures you see quoted, it is useful context before you start.

How does the titration schedule actually work, and what should you expect?

Wegovy starts at 0.25mg weekly. After roughly four weeks, the prescriber typically moves to 0.5mg, then 1mg, then 1.7mg, and finally 2.4mg, each step around a month apart. The full breakdown of the Wegovy dose schedule covers what each stage looks like and what the clinical purpose of each step is.

Side effects tend to be most noticeable in the days following a dose increase, particularly nausea and changes in bowel habit. For most people they ease within one to two weeks as the body adjusts. They do not necessarily worsen linearly with each increase, some people find the jump from 0.5mg to 1mg harder than later steps, others the reverse. There is genuine individual variation here.

If you are weighing up the treatment or thinking about starting, it helps to go in with realistic expectations: the full weight-loss benefit of Wegovy typically becomes clearest in the second half of the titration, not at week four. Patience with the process tends to produce better outcomes than pressure to accelerate it. A free consultation with a GPhC-registered prescriber is the right place to discuss which starting point and pace makes sense for your circumstances.